186 related articles for article (PubMed ID: 34462984)
1. Combination of anlotinib and gemcitabine promotes the G0/G1 cell cycle arrest and apoptosis of intrahepatic cholangiocarcinoma in vitro.
Fan S; Ge Y; Liu J; Liu H; Yan R; Gao T; Fan X; Xiao Z; An G
J Clin Lab Anal; 2021 Oct; 35(10):e23986. PubMed ID: 34462984
[TBL] [Abstract][Full Text] [Related]
2. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
[TBL] [Abstract][Full Text] [Related]
4. Metformin potentiates the anticancer activities of gemcitabine and cisplatin against cholangiocarcinoma cells in vitro and in vivo.
Zhu HQ; Ma JB; Song X; Gao HJ; Ma CQ; Chang H; Li HG; Liu FF; Lu J; Zhou X
Oncol Rep; 2016 Dec; 36(6):3488-3496. PubMed ID: 27779693
[TBL] [Abstract][Full Text] [Related]
5. Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma.
Tang H; You T; Ge H; Gao J; Wang Y; Bai C; Sun Z; Han Q; Zhao RC
Int Immunopharmacol; 2024 May; 133():112053. PubMed ID: 38615380
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor screening identifies HC toxin as the most effective in intrahepatic cholangiocarcinoma cells.
Zhou W; Chen X; He K; Xiao J; Duan X; Huang R; Xia Z; He J; Zhang J; Xiang G
Oncol Rep; 2016 May; 35(5):2535-42. PubMed ID: 26935789
[TBL] [Abstract][Full Text] [Related]
7. [Microwave Hyperthermia Combined with Gemcitabine Inhibits Proliferation
and Induces Apoptosis of Human Lung Squamous Carcinoma Cells].
Yang Y; Zhao Y; Ma S; Yang D
Zhongguo Fei Ai Za Zhi; 2018 Nov; 21(11):805-814. PubMed ID: 30454541
[TBL] [Abstract][Full Text] [Related]
8. Anti-cancer Drug Anlotinib Promotes Autophagy and Apoptosis in Breast Cancer.
Chen S; Gao Y; Zhu P; Wang X; Zeng L; Jin Y; Zhi X; Yang H; Zhou P
Front Biosci (Landmark Ed); 2022 Apr; 27(4):125. PubMed ID: 35468684
[TBL] [Abstract][Full Text] [Related]
9. Advanced intrahepatic cholangiocarcinoma treated using anlotinib and microwave ablation: A case report.
Zhang A; Liu B; Xu D; Sun Y
Medicine (Baltimore); 2019 Dec; 98(52):e18435. PubMed ID: 31876723
[TBL] [Abstract][Full Text] [Related]
10. Effects and Mechanisms of Anlotinib and Dihydroartemisinin Combination Therapy in Ameliorating Malignant Biological Behavior of Gastric Cancer Cells.
Luo Q; Zhang S; Zhang D; Feng R; Li N; Chen W; Chen X; Yang S
Curr Pharm Biotechnol; 2021; 22(4):523-533. PubMed ID: 32576126
[TBL] [Abstract][Full Text] [Related]
11. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
[TBL] [Abstract][Full Text] [Related]
12. Interplay Between Gemcitabine and Erlotinib Over Pancreatic Adenocarcinoma Cells.
Torres C; Linares A; Alejandre MJ; Palomino-Morales RJ; Delgado JR; Perales S
Pancreas; 2016 Feb; 45(2):269-80. PubMed ID: 26495790
[TBL] [Abstract][Full Text] [Related]
13. Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer without harboring EGFR T790M mutation.
Lian Z; Du W; Zhang Y; Fu Y; Liu T; Wang A; Cai T; Zhu J; Zeng Y; Liu Z; Huang JA
Thorac Cancer; 2020 Jul; 11(7):1934-1943. PubMed ID: 32433828
[TBL] [Abstract][Full Text] [Related]
14. Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer.
Zhang C; Cao H; Cui Y; Jin S; Gao W; Huang C; Guo R
Thorac Cancer; 2021 Oct; 12(19):2574-2584. PubMed ID: 34510760
[TBL] [Abstract][Full Text] [Related]
15. Induction of caspase mediated apoptosis and down-regulation of nuclear factor-κB and Akt signaling are involved in the synergistic antitumor effect of gemcitabine and the histone deacetylase inhibitor trichostatin A in human bladder cancer cells.
Jeon HG; Yoon CY; Yu JH; Park MJ; Lee JE; Jeong SJ; Hong SK; Byun SS; Lee SE
J Urol; 2011 Nov; 186(5):2084-93. PubMed ID: 21944112
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumour effects of triptolide plus gemcitabine in bladder cancer.
Yang Y; Zhang LJ; Bai XG; Xu HJ; Jin ZL; Ding M
Biomed Pharmacother; 2018 Oct; 106():1307-1316. PubMed ID: 30119201
[TBL] [Abstract][Full Text] [Related]
17. Anlotinib Inhibits Cell Proliferation, Migration and Invasion via Suppression of c-Met Pathway and Activation of ERK1/2 Pathway in H446 Cells.
Tang X; Zheng Y; Jiao D; Chen J; Liu X; Xiong S; Chen Q
Anticancer Agents Med Chem; 2021; 21(6):747-755. PubMed ID: 32682383
[TBL] [Abstract][Full Text] [Related]
18. Pristimerin causes G1 arrest, induces apoptosis, and enhances the chemosensitivity to gemcitabine in pancreatic cancer cells.
Wang Y; Zhou Y; Zhou H; Jia G; Liu J; Han B; Cheng Z; Jiang H; Pan S; Sun B
PLoS One; 2012; 7(8):e43826. PubMed ID: 22952775
[TBL] [Abstract][Full Text] [Related]
19. Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity.
Lin G; Lin KJ; Wang F; Chen TC; Yen TC; Yeh TS
Dis Model Mech; 2018 May; 11(8):. PubMed ID: 29666220
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of the effects of gemcitabine against pancreatic cancer by oridonin via the mitochondrial caspase-dependent signaling pathway.
Liu DL; Bu HQ; Jin HM; Zhao JF; Li Y; Huang H
Mol Med Rep; 2014 Dec; 10(6):3027-34. PubMed ID: 25242370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]